Lemborexant
Treatment for Insomnia
Typical Dosage: 5-10 mg at bedtime
Effectiveness
65%
Safety Score
55%
Clinical Trials
21
Participants
6K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
5-10 mg at bedtime
Time to Effect
immediate
Treatment Duration
long-term
Evidence Quality
HIGHNumber Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
25(Treat 25 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$2,000
Monitoring:$150
Side Effect Mgmt:$50
Total Annual:$2,200
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$180,000/QALY
QALYs Gained
0.12
Outcome-Based Costs
Cost per Responder
$4,000
Cost per Remission
$18,333
Active Clinical Trials
10 active trials recruiting for Lemborexant in Insomnia
Patient-Reported Outcomes for Lemborexant in Chinese Participants With Insomnia
NCT06225947RECRUITING
200 participants
OBSERVATIONAL
Guangzhou, China +4 more
Started: Feb 22, 2024
Lemborexant vs Zopiclone vs Clonidine for Insomnia Treatment in Chronic Pain Patients
NCT05618002RECRUITING
150 participants
OBSERVATIONAL
Surrey, Canada
Started: Nov 8, 2022
A Dual Orexin Receptor Antagonist to Reduce Biomarkers of Neurodegeneration in Adults With Insomnia.
NCT06823752RECRUITINGPHASE2
20 participants
INTERVENTIONAL
Macquarie Park, Australia
Started: May 13, 2025
Lemborexant for Insomnia in a Patient With Dementia: An N-of-1 Trial
NCT06093126RECRUITINGPHASE4
1 participants
INTERVENTIONAL
Halifax, Canada
Started: Dec 11, 2023
Efficacy of CBT-I and Lemborexant Medication for Different Subtypes of Chronic Insomnia
NCT06779149RECRUITINGNA
90 participants
INTERVENTIONAL
Québec, Canada
Started: Apr 1, 2025
Lemborexant for the Treatment of Residual Insomnia in Major Depressive Disorder (MDD)
NCT06843187NOT YET RECRUITINGPHASE2
30 participants
INTERVENTIONAL
Toronto, Canada
Started: Feb 1, 2025
Lemborexant Treatment of Insomnia Linked to Epilepsy
NCT06262594RECRUITINGPHASE3
26 participants
INTERVENTIONAL
Durham, United States +1 more
Started: Oct 29, 2024
Lemborexant on Improving Sleep Quality Among Hospital Rotating Shift Workers
NCT06496282RECRUITINGPHASE3
50 participants
INTERVENTIONAL
Ratchathewi, Thailand
Started: Aug 1, 2024
Effects of Lemborexant on Insomnia and Its Relationship to Mood and Behavior on Opioid Use Disorder Subjects
NCT06981195RECRUITINGPHASE2
100 participants
INTERVENTIONAL
Richmond, United States
Started: May 27, 2025
Lemborexant to Prevent Post-operative Delirium in Cardiac Surgery Patients
NCT06648681NOT YET RECRUITINGPHASE2
60 participants
INTERVENTIONAL
Vancouver, Canada
Started: May 1, 2025
Completed Clinical Trials
10 completed trials for Lemborexant in Insomnia
Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2)
NCT02952820COMPLETEDPHASE3
971 participants
INTERVENTIONAL
Chandler, United States +113 more
Started: Nov 15, 2016
Study to Evaluate the Effect of 2 Dosage Strengths of Lemborexant (E2006) on a Multiple Sleep Latency Test in Participants With Insomnia Disorder
NCT02350309COMPLETEDPHASE1
69 participants
INTERVENTIONAL
Atlanta, United States +1 more
Started: Dec 13, 2014
A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006
NCT01463098COMPLETEDPHASE1
122 participants
INTERVENTIONAL
New York, United States +1 more
Started: Oct 5, 2011
Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)
NCT02783729COMPLETEDPHASE3
1.01K participants
INTERVENTIONAL
Jasper, United States +101 more
Started: May 31, 2016
A Study to Evaluate Next-Dose Transition From Zolpidem to Lemborexant (LEM) for the Treatment of Insomnia
NCT04009577COMPLETEDPHASE3
53 participants
INTERVENTIONAL
Glendale, United States +16 more
Started: Jul 15, 2019
A Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreational Sedative Users
NCT03158025COMPLETEDPHASE1
39 participants
INTERVENTIONAL
Toronto, Canada
Started: Apr 19, 2017
A Study of Lemborexant in Chinese Participants With Insomnia Disorder
NCT04549168COMPLETEDPHASE3
194 participants
INTERVENTIONAL
Beijing, China +22 more
Started: Nov 6, 2020
A Study to Assess the Pharmacodynamics of Lemborexant in Korean Participants With Insomnia Disorder
NCT05594589COMPLETEDPHASE2
65 participants
INTERVENTIONAL
Seongnam-si, South Korea +8 more
Started: Nov 30, 2022
A Study to Evaluate the Safety of DAYVIGO (Lemborexant) Tablets in Participants With Insomnia.
NCT04573556COMPLETED
550 participants
OBSERVATIONAL
Nagoya, Japan +2 more
Started: Oct 17, 2020
An Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Transitioning to Lemborexant in Japanese Subjects With Insomnia
NCT04742699COMPLETEDPHASE4
97 participants
INTERVENTIONAL
Kitakyushu, Japan +8 more
Started: Mar 24, 2021
Showing 20 of 21 total trials